Advertisement

Emergencies in Movement Disorders

  • Julieta E. ArenaEmail author
Chapter

Abstract

Movement disorders is not an area of neurology known to have many clinical emergencies. However, their recognition is very important since urgent care can be needed in these cases. In this chapter we will review the more frequent and more severe emergencies in movement disorders, going from their cause to the diagnosis and treatment approach. For practical purposes, we will classify movement disorders emergencies in either hypokinetic or hyperkinetic. As it is the case for all movement disorders, careful history of the patient and physical examination is key to a correct identification of the problem and treatment strategy approach. For acute movement disorders presenting in the Emergency Department or in the hospital, a diligent review of medications taken by the patients is particularly necessary.

Keywords

Movement disorders Emergency Drug-induced movement disorders Acute parkinsonism Acute chorea Acute dystonia Status dystonicus Myoclonus Tic status 

References

  1. 1.
    Poston KL, Frucht SJ. Movement disorder emergencies. J Neurol. 2008;255(Suppl 4):2–13.CrossRefGoogle Scholar
  2. 2.
    Munhoz RP, Scorr LM, Factor SA. Movement disorders emergencies. Curr Opin Neurol. 2015;28(4):406–12.3.CrossRefGoogle Scholar
  3. 3.
    Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185–202.CrossRefGoogle Scholar
  4. 4.
    Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986;73:337–47.CrossRefGoogle Scholar
  5. 5.
    Hashim H, Zeb-un-Nisa ASA, Al Madani AA. Drug resistant neuroleptic malignant syndrome and the role of electroconvulsive therapy. J Pak Med Assoc. 2014 Apr;64(4):471–3.PubMedGoogle Scholar
  6. 6.
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112.CrossRefGoogle Scholar
  7. 7.
    Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–13.CrossRefGoogle Scholar
  8. 8.
    Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–42.CrossRefGoogle Scholar
  9. 9.
    Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277–85.CrossRefGoogle Scholar
  10. 10.
    Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49:871–4.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Lee PC, Brice A, Vidailhet M, Elbaz A, DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018. [Epub ahead of print].Google Scholar
  12. 12.
    Rabinak CA, Nirenberg MJ. Dopamine Agonist Withdrawal Syndrome in Parkinson Disease. Arch Neurol. 2010;67(1):58–63.CrossRefGoogle Scholar
  13. 13.
    Genel F, Arslanoglu S, Uran N, Saylan B. Sydenham’s chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain and Development. 2002;24(2):73–6.CrossRefGoogle Scholar
  14. 14.
    Oh SH, Lee KY, Im JH, Lee MS. Chorea associated with non-ketotic hyperglycemia and hyperintensity basal ganglia lesion on T1-weighted brain MRI study: meta-analysis of 53 cases including four present cases. J Neurol Sci. 2002;200(1–2):57–62.CrossRefGoogle Scholar
  15. 15.
    Manji H, Howard RS, Miller DH, et al. Status dystonicus: the syndrome and its management [published correction appears in Brain. 2000;123(pt 2):419]. Brain. 1998;121(pt 2):243–52.CrossRefGoogle Scholar
  16. 16.
    Wijdicks EFM, Hijdra A, Young GB, Bassetti CL, Wiebe S. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;67(2):203–10.CrossRefGoogle Scholar
  17. 17.
    Braksick SA, Rabinstein AA, Wijdicks EF, Fugate JE, Hocker S. Post-ischemic myoclonic status following cardiac arrest in young drug users. Neurocrit Care. 2017;26(2):280–3.CrossRefGoogle Scholar
  18. 18.
    Dalic LJ, Fennessy G, Edmonds M, Carney P, Opdam H, Archer J. Early electroencephalogram does not reliably differentiate outcomes in post-hypoxic myoclonus. Crit Care Resusc. 2019;21(1):45–52.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Movement Disorders Section, Neurology DepartmentFleni, Buenos AiresArgentina

Personalised recommendations